FDA has granted accelerated approval to polatuzumab vedotin
The drug, also known as Polivy, originated from Dr. Seon’s lab at Roswell Park
Now approved as part of treatment combination for aggressive lymphoma type
BUFFALO, N.Y. — A cancer therapy based on the work of Ben Seon, PhD, at Roswell Park Comprehensive Cancer Center has been approved by the U.S. Food and Drug Administration (FDA) for patients with an aggressive form of non-Hodgkin lymphoma. On June 10, the FDA granted...